共 6 条
- [1] Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR studyEUROPEAN HEART JOURNAL, 2012, 33 : 280 - 280Brinton, E.Ballantyne, C.Bays, H.Kastelein, J.Braeckman, R.Soni, P.
- [2] Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR studyCARDIOVASCULAR DIABETOLOGY, 2013, 12Brinton, Eliot A.Ballantyne, Christie M.Bays, Harold E.Kastelein, John J.Braeckman, Rene A.Soni, Paresh N.
- [3] Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR studyCardiovascular Diabetology, 12Eliot A BrintonChristie M BallantyneHarold E BaysJohn J KasteleinRene A BraeckmanParesh N Soni
- [4] AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A2, and High-sensitivity C-reactive Protein Levels in Patients With High Triglycerides and on Background Statin Therapy (the ANCHOR Study)CIRCULATION, 2011, 124 (21)Ballantyne, Christie M.Bays, Harold E.Kastelein, John J.Stein, Evan A.Isaacsohn, JonathanBraeckman, Rene A.Soni, Paresh N.
- [5] Effects of ezetimibe added to on-going statin therapy on LDL-C goal attainment in high risk hypercholesterolemic patients with or without type 2 diabetes mellitusDIABETES, 2003, 52 : A133 - A133Simons, LTonkon, MShah, AMaccubbin, DGumbiner, B
- [6] Effects of ezetimibe added to on-going statin therapy on LDL-C goal attainment in high risk hypercholesterolemic patients with or without Type 2 diabetes mellitusDIABETOLOGIA, 2003, 46 : A354 - A354Simons, LMasana, LTonkon, MShah, AMaccubbin, DGumbiner, B